December 9, 2025 – YaoPharma has entered into a license agreement with Pfizer Inc. Under the agreement, YaoPharma grants Pfizer an exclusive global license to develop, use, manufacture, and commercialize oral small molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient. The license covers all indications for therapeutic, diagnostic, and prophylactic human and veterinary use.

The licensed small molecule GLP-1R agonist was independently researched and developed by YaoPharma, which owns the independent intellectual property rights. It is intended for the treatment of metabolic diseases, with potential indications including but not limited to chronic weight management, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH, also known as non-alcoholic steatohepatitis or NASH), among others. YP05002 is currently in Phase 1 clinical development in Australia.

According to the agreement terms, YaoPharma grants Pfizer the exclusive global license for the further development, production, and commercialization of YP05002. YaoPharma will receive an upfront payment of $150 million and is eligible to receive up to $1.935 billion in milestone payments tied to certain development, registration, and commercial achievements, as well as tiered royalties on sales following approval.

YaoPharma R&D Laboratory

YaoPharma is a group-based, national key high-tech enterprise with a complete pharmaceutical industry chain integrating API and finished dosage form R&D, production, and sales. Headquartered in Chongqing, it is controlled by Fosun Pharma (600196.SH;02196.HK) and has Chongqing Pharmaceutical Group(000950.SZ)as a shareholder.

"The partnership with Pfizer marks the international recognition of YaoPharma's R&D capabilities. We firmly believe that only through openness and collaboration can the value of innovation be maximized," stated Mr. Liu Qiang, Chairman of YaoPharma. "By leveraging Pfizer's exceptional global development experience and commercialization network, along with YaoPharma's profound expertise in small molecule R&D and manufacturing, our shared goal is to accelerate the global development and commercialization of this innovative drug, thereby benefiting patients worldwide more rapidly and extensively."

YaoPharma Headquarters